

Family Physician Roles in Smoking Cessation in Primary Care

¹Dr. Tahani Ahmed Bukhari, ²Dr. Haneen Ahmed Bukhari, ³Dr. Fatimah Husni Rajab,
⁴Dr. Sara Bejad Hazza Al_otibi, ⁵Dr. Reham Othman Hasan Althomali,
⁶Dr. Afnan Faleh Alharthi, ⁷Dr. Bayan Abdullah Hamed Alnemari,
⁸Dr. Munirah Hamad Alsahel

Abstract: This article summarizes the current smoking cessation guidelines that can serve as an effective framework for tobacco cessation intervention in primary care, such as pharmacological and psychological help. A comprehensive search of the literature was conducted in the following databases; PubMed, and SciVerse Scopus for studies published before December 2017. During the first stage the above databases were searched using the following search criteria. The clinician needs to play a front line role due to the fact that. The promotion of cigarette smoking cessation need to be a top priority for clinicians and for governments. The family physician is main to reaching as numerous smokers as possible and aiding them quit. The combination of brief, empathetic and appropriate interventions, assistance and pharmacological therapies can assist motivate smokers to quit and provide their ideal opportunity to live smoke-free. Recognition of smokers and providing suggestions and support for cessation need to be a regular part of practice in primary care clinics; therefore.

Keywords: Family Physician, smoking cessation, pharmacological.

1. INTRODUCTION

Caffeine, nicotine and ethyl alcohol are the 3 most extensively eaten psychoactive representatives worldwide [1]. Tobacco, particularly smoking, has long been identified as a health danger. Since 1964 succeeding Surgeon Generals have warned the general public concerning the threats of smoking cigarettes [2].

Cigarette smoking is a major preventable risk variable for the advancement of non-communicable illness, including cancers, cardiovascular and respiratory conditions [3]. Consequently, 12% of all grown-up fatalities worldwide are attributable to cigarette usage [4]. Overall, amongst those aged 15 years and over, the worldwide prevalence of tobacco usage is 22%. Smoking prevalence is, nevertheless, substantially greater amongst males (36%) than women (8%) [5], with large variation throughout countries varying in between 22% (Brazil) and 60.6% (Russia) among males, and between 0.6% (Egypt) and 28.7% (Bangladesh) amongst females [5], [6].

Long-term cigarette smoking cessation substantially minimizes health dangers [7] and brings about a decline in the risk of early mortality. Across the country implemented services for smoking cessation support, such as face-to-face support [8] and give up lines, [9] have been discovered to be efficient in assisting smokers to give up. Easy accessibility to such smoking cigarettes cessation treatment and assistance has additionally shown to raise stop rates [10].

In lots of nations, smokers are usually recognized, suggested and provided give up assistance in a primary care setting [11]. In nations with well-known professional cessation services (e.g., face-to-face solutions and/or give up lines), general method is the optimum setting for the identification and referral of smokers to happen. As an example, in the UK nearly 300 million smoking cigarettes cessation assessments a year and around 90% of all National Health Service get in touches with take place in a general technique establishing [12]. Evidence for the performance of treatments in this setup is well developed; rates of cigarette smoking abstinence are raised when wellness experts recognize smokers, punctual quit efforts, and provide support to quit cigarette smoking, including pharmacotherapy.

This article summarizes the current smoking cessation guidelines that can serve as an effective framework for tobacco cessation intervention in primary care, such as pharmacological and psychological help.

2. METHODOLOGY

A comprehensive search of the literature was conducted in the following databases; PubMed, and SciVerse Scopus for studies published before December 2017. During the first stage the above databases were searched using the following search criteria. The PubMed database was searched using the MeSH (Medical Subject Headings) term “smoking”, “cessation”, “Primary care”. The Web of Science database was searched using same search terms. and our search was restricted to only English language studies with human subjects.

3. DISCUSSION

• Clinical intervention framework for smoking cessation:

Cigarette smoking cessation is the most vital, cost-effective preventative maintenance that medical professionals could provide patients who smoke. It has been called the "gold standard" of prevention treatments by David Eddy, a leading authority on standards and cost-effectiveness analysis [13]. Primary care medical professionals play an essential duty in identification, analysis and therapy of cigarette smokers. It is necessary to give cessation intervention for all smokers at each visit. At the very least 70% of cigarette smokers see a physician every year, which suggests that doctors are missing out on a prime chance to improve the health of their patients [15].

Brief guidance and inspiration throughout one routine office visit causes a 5% estimated stopped rate without regression at 1 year [16]. Greater stopped rates are possible with even more fully developed programs. With an empathic, individualized cigarette smoking cessation treatment program, cigarette smokers that stay away for 5 years are likely to continue to be abstinent after 11 years [17].

Effective cigarette smoking prevention treatments based upon the National Cancer Institute's "Five A's" model, the Agency for Healthcare Research and Quality guidelines, and the Transtheoretical Model (TTM) of behavioral change, have been shown to be effective in recognizing and dealing with tobacco individuals [14].

• Clinical practice guideline:

A partnership in between the Federal Government and non-profit organizations (Agency for Healthcare Research and Quality; Centers for Disease Control and Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; Robert Wood Johnson Foundation; and University of Wisconsin Medical School's Center for Tobacco Research and Intervention) developed the present Clinical Practice Guideline, "Treating Tobacco Use and Dependence." This guideline integrates the "Five A's" design [18].

- Ask about smoking.
- Advise smokers to stop.
- Assess the smoker's willingness to stop.
- Assist those smokers willing to stop.
- Arrange follow-up.

Systematically determine all tobacco customers by Asking at every visit. Offer clear, strong and personalized Advice regarding the significance of complete cessation. Patients not willing to stop in spite of clinical guidance might be uninformed, worried concerning the impacts of quitting, or discouraged by previous regressions. Once recognized, a smoking cigarettes Assessment kind need to be used for all patients and the info upgraded by putting a smoker identifier sticker on the chart. The Fagerström test (Therapeutic Guidelines Limited, North Melbourne, Australia) for nicotine reliance (table 1) has confirmed useful in identifying the patient's level of nicotine dependancy, most likely intensity of withdrawal signs and symptoms, difficulty in quitting and feasible need for higher doses of nicotine supplements.

Table 1: Fagerström test for nicotine dependence [31]

	0	1	2	3
1. How soon after you wake up do you smoke your first cigarette?	More than 1 hour	1/2 to 1 hour	6 to 30 minutes	5 minutes or less
2. Do you find it difficult to refrain from smoking in smoking in places where it is		No	Yes	

forbidden (e.g., in church, at the library, in a movie theater)?				
3. Which cigarette would you most hate to give up?		Any other	First one in the morning	
4. How many cigarettes do you smoke per day?	Less than 10	11 to 20	21 to 30	More than 31
5. Do you smoke more frequently during the first hours after waking than during the rest of the day?		No	Yes	
6. Do you smoke when you are so ill that you are in bed most of the day?		No	Yes	

Scoring: 0–4 low; 5 medium; 6–7 high; 8–10 very high level of nicotine dependence. A total of 7 or greater may indicate more severe withdrawal symptoms, greater difficulty quitting, and possibly the need for higher dose nicotine supplements.

Pledge to *Assist* patients when they are ready to quit[19]. Ask questions at each visit that help the patient identify reasons to quit and barriers to quitting. Motivational interventions for patients unwilling to quit at the present time are characterized by the “Five R's”:

- Relevance
- Risks
- Rewards
- Roadblocks
- Repetition (table 2)

Table 2: Enhancing motivation to quit tobacco use-the “Five R's” for the patient unwilling to quit at this time.[18]

Relevance	Encourage the patient to show why quitting is directly pertinent, being as certain as feasible. Motivational information has the best effect if it relates to a patient's condition or risk, family or social situation (e.g., having children in the residence), health worries (morning cough, better sense of taste and scent, much better breath) age, sex, and other essential patient characteristics (e.g., prior quitting experience, personal barriers to cessation).
Risks	The clinician should ask the patient to determine potential negative effects of tobacco usage. The clinician might suggest and highlight those that appear most relevant to the patient. The clinician should emphasize that smoking cigarettes low-tar/low-nicotine cigarettes or using various other kinds of tobacco (e.g., chewing tobacco, stogies, and pipelines) will not eliminate these threats. Examples of risks are: - <i>Acute risks</i> : lack of breath, exacerbation of asthma, harm to pregnancy, impotence, infertility, increased serum carbon monoxide degrees. - <i>Long-term dangers</i> : myocardial infarction and strokes, lung and other cancers (larynx, mouth, vocal cords, esophagus, pancreas, bladder, cervix), chronic obstructive pulmonary diseases (chronic bronchitis and emphysema), long-term impairment and require for prolonged care. - <i>Environmental risks</i> : enhanced risk of lung cancer and heart condition in spouses; higher rates of smoking by children of tobacco users; raised risk for low birth weight, unexpected infant death syndrome, asthma, middle ear illness, and breathing infections in kids of smokers.
Rewards	The clinician should ask the patient to determine possible benefits of improved health: food will taste better; enhanced sense of odor; save loan; feel far better about yourself; house, car, clothing, and breath will certainly smell much better; can quit bothering with giving up; set an example for youngsters; have much healthier children and youngsters; not fret concerning subjecting others to smoke; feel better physically; execute far better in physical activities; minimized wrinkling/aging of skin.
Roadblocks	The clinician ought to ask the patient to determine barriers or obstacles to quitting and note components of treatment (trouble solving, pharmacotherapy) that could address barriers. Typical barriers could include: withdrawal signs and symptoms, fear of failure, weight gain, absence of assistance, depression, enjoyment of tobacco.

Repetition	The motivational intervention needs to be duplicated every single time an unmotivated patient visits the clinical setup. Tobacco customers that have failed in previous stopped efforts must be told that most individuals make duplicated stopped efforts prior to they are successful.
-------------------	--

Assist patients willing to quit by setting a quit date and preparing the patient for the quit day. A total stop quit date is incredibly essential to success. Smoking cigarettes 0-1 cigarettes each day/week during the very first 2 weeks has extremely high predictive worth for failure [21]. On top of that, give self-help materials, quitting recommendations and nicotine replacement therapy (NRT). A smoking agreement can be useful to develop a quit date and having the patient merely state; [20] "I comprehend that quitting smoking cigarettes is the single ideal thing I could do for my health which my health professional has highly encouraged me to quit."

Make patients conscious of nicotine withdrawal signs so they know exactly what to expect (table 3). If the clinician and patient feel a more extensive therapy is warranted, the patient can be described an extensive therapy program. Prepare follow-up contact for all patients attempting to quit [14], [15]. Figure 1 diagrams a flow chart of the present smoking cessation standards. Relapse into smoking can take place at any stage, at which point efforts need to be restored at the level ideal to the patient.




Figure 1: Smoking cessation flow chart

Table 3: Nicotine withdrawal symptoms [22]

	Frequency of occurrence
Anxiety	88%
Irritability	80%
Difficulty concentrating	73%
Restlessness	71%
Tobacco craving	62%
Gastrointestinal problems	33%
Headaches	24%
Drowsiness	22%

• **Pharmacotherapy:**

Nicotine is fast-acting, showing up in the brain within 7 seconds of inhalation. It promotes the adrenal glands resulting in discharge of epinephrine, leading to the "kick" or "repair" experienced by the smoker. The rush of adrenaline triggers a sudden release of glucose, a rise in blood pressure, and boosted respiratory and heart rates. Nicotine additionally suppresses insulin outcome producing a chronic slight hyperglycemia. In the brain nicotine creates dopamine release and reduces the inhibitory (gamma amino butyric acid) reaction in regions controlling enjoyment and inspiration. Even a brief direct exposure to nicotine results in the long-lasting excitation of the brain's reward locations [23], [24].

Pharmacotherapy can be divided right into two groups: nicotine replacement therapy (NRT) and non-NRT. NRT raises abstinence rates by 2 to 3 times that of placebo [15]. All pharmacotherapy therapies roughly double the cessation rates. Therefore, patient preference and previous experience is the basis for treatment option. Table 4 lists the advantages and disadvantages of each pharmacologic therapy choice.

Table 4: Advantages and disadvantages of pharmacologic treatments for smoking cessation [26]

Treatment	Advantages	Disadvantages
Patch and/or gum	Available over the counter	Not approved by FDA; avoid use with dentures; temporomandibular joint disorder; adhesive allergies
Nicotine nasal spray	Higher, quicker nicotine levels	Unpleasant adverse events initially; avoid use with chronic nasal allergies
Nicotine inhaler	Mimics hand-to-mouth behavior	Low nicotine levels
Bupropion hydrochloride	Non-nicotine; can be used in combination with patch; decreased weight gain; mood stabilization with nicotine withdrawal	Must screen for seizures

NRT is not suggested for patients in instant post myocardial infarction (within 4 weeks), patients with serious arrhythmias, worsening angina pectoris, or pregnant and lactating females. NRT functions by replacing nicotine from cigarettes and relieving or avoiding nicotine withdrawal signs. Non-NRT alters or alleviates withdrawal signs and symptoms also.

Absorption from NRT-like gum and patches is gradual and time is enabled development of tolerance to nicotine withdrawal in the brain. The stimulant and euphoric results of rapidly soaked up nicotine from cigarette smoking does not take place. Nevertheless, the high degrees of pure nicotine preserved in the brain by NRTs prevent the nicotine withdrawal signs and symptoms and thus the efficacy of NRT [25].

Clinicians may recommend any one of 5 pharmacotherapies: nicotine gum, nicotine patch, nicotine nasal spray, nicotine inhaler and non-NRTs [26]. Just like all pharmacologic treatments, concomitant individual and telephone therapy substantially increase cessation rates [27].

To improve the safety and efficiency of all the pharmacologic representatives for nicotine withdrawal, give created instructions for appropriate usage, individualize dose and duration of therapy, schedule regular workplace check outs or phone calls to keep an eye on patient feedback, and adjust dosage and duration of treatment appropriately [28]. The patient ought to be checked every 1 to 2 weeks. Medicines should be recommended in 2-week doses. If abstaining is not accomplished within 2 weeks, again deal with medications and motivations. Discontinue therapy if smoking is at or near initial levels after 4 weeks. If previous not successful efforts were with a solitary medication change to mix treatment.

Carriers need to additionally understand that urine examinations are offered for monitoring patients if considered needed and suitable. Breath carbon monoxide concentration has been demonstrated to provide a very easy, noninvasive and instant method of assessing a patient's smoking cigarettes status [29]. Cotinine, a metabolite of nicotine secreted in the pee, could be utilized to keep an eye on NRT adherence, but could not differentiate NRT versus cigarette resources [29]. Anabasine and anatabine are tobacco alkaloids (not nicotine metabolites) that are eliminated in the pee and could be made use of to validate abstinence or measure the level of cigarette use in persons undertaking NRT [30].

4. CONCLUSION

The deleterious effects of cigarette use are well understood by both patients and clinicians. However, that knowledge does not currently translate efficiently into patients quitting. A concerted, office-wide initiative that consists of office nursing and assistant staff should be made to determine, inform and treat patients that utilize tobacco. Proven, brief, recurring,

guided interventions customized to the requirements of the patient and behavior phase, can enhance effective cessation attempts. Pharmacotherapy is available to assist patients struggling with nicotine addiction and dependence, and to give them tools to move through the behavioral stages. All doctor are obliged to utilize these tested methods to promote for the patient's better health. Advantages stand to be gotten not just by the tobacco user, however likewise non-users, health insurers, healthcare organizations and society as a whole. The clinician needs to play a front line role due to the fact that. The promotion of cigarette smoking cessation need to be a top priority for clinicians and for governments. The family physician is main to reaching as numerous smokers as possible and aiding them quit. The combination of brief, empathetic and appropriate interventions, assistance and pharmacological therapies can assist motivate smokers to quit and provide their ideal opportunity to live smoke-free. Recognition of smokers and providing suggestions and support for cessation need to be a regular part of practice in primary care clinics; therefore.

REFERENCES

- [1] Greden JF, Pomerleau O. Caffeine-related disorders and nicotine-related disorders. In: Kaplan HI, Sadock BJ, Cancro R, editors. *Comprehensive Textbook of Psychiatry*. 6th ed. Baltimore: Williams & Wilkins; 1995. pp. 806–811.
- [2] Centers for Disease Control and Prevention, author. Tobacco Information and Prevention Source (TIPS) Surgeon General's Reports. [June 5, 2003]; Available at: <http://www.cdc.gov/tobacco/sgrpage.htm>.
- [3] US Department of Health and Human Services. *The Health Consequences of Smoking: A Report of the Surgeon General*. (U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta (GA), 2004).
- [4] World Health Organisation. *WHO Global Report: Mortality Attributable to Tobacco*. (WHO, Geneva, 2012).
- [5] World Health Organisation. *World Health Statistics 2014*. (WHO, Geneva, 2014).
- [6] Giovino GA, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. *Lancet*. 2012;380:668–679. doi: 10.1016/S0140-6736(12)61085-X.
- [7] US Department of Health and Human Services. *The Health Benefits of Smoking Cessation: A Report of the Surgeon General*. (U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Rockville (MD), 1990).
- [8] Bauld L, Bell K, McCullough L, Richardson L, Greaves L. The effectiveness of NHS smoking cessation services: a systematic review. *J. Public Health*. 2010;32:71–82. doi: 10.1093/pubmed/fdp074.
- [9] Miller CL, Wakefield M, Roberts L. Uptake and effectiveness of the Australian telephone Quitline service in the context of a mass media campaign. *BMJ Tobacco Control*. 2003;12:53–58.
- [10] Levy DT, Chaloupka F, Gitchell J. The effects of tobacco control policies on smoking rates: a tobacco control scorecard. *J. Public Health Manag. Pract.*. 2004;10:338–353. doi: 10.1097/00124784-200407000-00011.
- [11] Pine-Abata H, et al. A survey of tobacco dependence treatment services in 121 countries. *Addiction*. 2013;108:1476–1484. doi: 10.1111/add.12172.
- [12] The King's Fund. *General Practice in England: An Overview*. (The King's Fund, 2009).
- [13] Eddy DM. David Eddy ranks the tests. *Harv Health Lett*. 1992;17:10–11.
- [14] The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. *JAMA*. 1996; 275:1270–1280.
- [15] Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, Heyman RB, Jaén CR, Kottke TE, Lando HA, Mecklenburg RE, Mullen PD, Nett LM, Robinson L, Stitzer ML, Tommasello AC, Villejo L, Wewers ME. *Treating tobacco use and dependence*, June 2000. U.S. Department of Health and Humans Services, Public Health Service. [June 6, 2003].
- [16] Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. *Arch Intern Med*. 1995;155:1933–1941.

- [17] Murray RP, Connett JE, Rand CS, Pan W, Anthonisen NR. Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. *Prev Med.* 2002;35:314–319.
- [18] Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives, author. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. *JAMA.* 2000;283:3244–3254.
- [19] Treating tobacco use and dependence—a systems approach. A guide for health care administrators, insurers, managed care organizations, and purchasers, November 2000. U.S. Public Health Service. [June 6, 2003]. Available at <http://www.surgeongeneral.gov/tobacco/systems.htm>.
- [20] Glynn TJ, Manley MW. How to help your patients stop smoking: a National Cancer Institute manual for physicians. Bethesda, MD: National Cancer Institute; 1993. NIH publication no 93-3064.
- [21] Tønnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, Rijcken B, Sawe U Collaborative European Anti-Smoking Evaluation. European Respiratory Society, author. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. *Eur Respir J.* 1999;13:238–246.
- [22] Centers for Disease Control and Prevention, author. The health consequences of smoking: nicotine addiction—a report by the Surgeon General. Rockville, MD: US Department of Health and Human Services, Public Health Service; 1988. DHHS publication no. (CDC)88-8406.
- [23] Mansvelder HD, Keath JR, McGehee DS. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. *Neuron.* 2002;33:905–919.
- [24] National Institute on Drug Abuse. Research report series -nicotine addiction. [June 6, 2003]. Available at: <http://www.nida.nih.gov/researchreports/nicotine/nicotine3.html>.
- [25] Benowitz NL. Cigarette smoking and nicotine addiction. *Med Clin North Am.* 1992;76:415–437.
- [26] Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. *JAMA.* 1999;281:72–76.
- [27] MacKenzie TD. New strategies for smoking cessation. *Hosp Pract.* 1999;34:25–26. 29.
- [28] Dale LC, Hurt RD, Hays JT. Drug therapy to aid in smoking cessation. Tips on maximizing patients' chances for success. *Postgrad Med.* 1998;104:75–78. 83–84.
- [29] Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. *Chest.* 2000;117:758–763.
- [30] Jacob P, 3rd, Hatsukami D, Severson H, Hall S, Yu L, Benowitz NL. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. *Cancer Epidemiol Biomarkers Prev.* 2002;11:1668–1673.
- [31] Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. *Br J Addict* 1991;86:1119–1127